News/ News/ R&D Lilly taps Lycia for protein degrader tech in $1.6bn deal Phil Taylor Eli Lilly, immunology, licensing, Lycia Therapeutics, pain, partnering, protein degradation 0 Comment Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share X Lilly taps Lycia for protein degrader tech in $1.6bn deal https://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/